MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies that are driving the next-generation of cell-based therapies and making a meaningful difference for patients. The Company's technology is employed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte has granted 13 strategic platform licenses to leading cell-based therapy developers. Through 2020, MaxCyte has granted licenses for more than 140 cell therapy programs, with over 100 licensed for clinical use. Our Flow Electroporation^® technology and next-generation ExPERT^® platform enable our partners to accelerate, streamline, and improve the drug development process from the early stages of research to commercialization. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, U.S.
 

PTC Therapeutics

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
 

AVROBIO

AVROBIO’s mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a program in Pompe disease. AVROBIO is powered by the plato™ gene therapy platform, our foundation designed to scale gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit our website, and follow us on Twitter and LinkedIn.

CSL Behring

Driven by Our Promise
It began with a promise. CSL Behring's parent company, CSL, was formed more than 100 years ago to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry. Our ability to innovate and deliver life-saving medicines for patients with rare disease and other unmet medical needs around the world has earned us a reputation for always putting patients first. We are CSL Behring and we are driven by our promise.
 

Intellia

Intellia Therapeutics is a leading gene editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia was named as one of the top 10 biotech start-ups by Nature Biotechnology. In September 2015, Intellia was named a “Fierce 15” biotech company by FierceBiotech. 

Pfizer France

Pfizer Inc.: Breakthroughs that change patients’ lives^®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

REGENXBIO Inc.

REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects.  We have developed a broad pipeline of gene therapy programs using our NAV^® Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.
 

Sarepta

Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for 6 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases.

Spark Therapeutics

At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. We have successfully applied our technology in the first gene therapy approved in both the U.S. and EU for a genetic disease, and currently have five programs in clinical trials. At Spark, we see the path to a world where no life is limited by genetic disease. Spark is a member of the Roche group. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.

Thermo Fisher Scientific

As the world leader in serving science, Thermo Fisher Scientific is uniquely positioned to provide the quality materials, services and support need to accelerate the pace of advanced therapy development. We understand the complexity of this rapidly-evolving industry and have made significant investments in cGMP raw material manufacturing and drug product manufacturing capabilities to provide innovative end-to-end solutions- from the acquisition of Brammer Bio to investing to expand our critical raw material manufacturing facilities. Partner with us to access the high-quality materials, services, and support you need from discovery to clinical research and commercial cell and gene manufacturing. Through our Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab services, Patheon, and Gibco brands, we offer an unmatched combination of innovative technologies, manufacturing, and distribution capabilities.

Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
 
For more information on Ultragenyx, please visit the Company's website at ultragenyx.com.

Beckman Coulter Life Sciences

Beckman Coulter Life Sciences is dedicated to developing and providing advanced technologies and equipment for research and discovery to explore new treatment methods. Our products include Liquid Handling and Genomic solutions, Particle Counting and Characterization, Centrifugation and Flow Cytometry, which are implemented in all major areas of Life Sciences such as biology, biochemistry, biophysics, nanotechnology and molecular biology to simplify and automate existing processes in the lab.

Our vision: Advancing science through discovery

Cevec Pharmaceuticals

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors, vaccines and complex recombinant proteins. With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents and cGMP plasmids. CEVEC’s CAP® Technology based on human suspension cells is the ideal production platform for RCA-free Adenoviral vectors, Lentiviral vectors, viral vaccines and exosomes. With the CAP-Go® Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.
 

Cytiva

Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

Genethon

Genethon, is a pioneer and a leader in the field of gene therapy for rare genetic diseases. Genethon has multiple ongoing programs at clinical, preclinical and research stage for neuromuscular, blood, immune system, and liver diseases. Several of these programs are pursued by Genethon as sponsor, others have been licensed to leading biotech and pharma players in the gene therapy arena such as Avexis/Novartis (to which Genethon licensed the founding patents for Zolgensma), Audentes, Gensight Biologics, Orchard Therapeutics, Spark.
Genethon has around 200 scientists and experts in its R&D center in Evry (France), covering R&D, bioprocess development, clinical and regulatory.
Genethon is a non-profit organization created in 1990 by the AFM-Telethon (French Muscular Dystrophy Association) which is its main funding source.
 

Human Gene Therapy

Established in 1990, Human Gene Therapy is the leading peer-reviewed journal publishing exceptional, multidisciplinary research embracing all aspects of gene therapy - from basic research to new technologies to clinical development. In 2020 the Journal marked three impressive decades by unveiling a dramatic new redesign and a renewed editorial mission. Human Gene Therapy serves as the Official Journal of ESGCT.

Oxford Biomedica

A leading, fully integrated, cell and gene therapy group focused on developing life-changing treatments for serious diseases, Oxford Biomedica is your partner of choice for viral vector development scale-up, analytics and GMP processing.
Leverage our expertise and state-of-the-art bioprocessing facilities and purpose built laboratories to help to achieve commercialisation of your viral vector-based products.
Using LentiVector®, our sector leading lentiviral vector platform, Oxford Biomedica develops in vivo and ex vivo products both in-house and with partners, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations.
Additionally, Oxford Biomedica has a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222.
Discover how we drive credible science to help you realise incredible results - visit www.oxb.com or email partnering@oxb.com.
 
 

uniQure

uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular technology platform to rapidly bring new disease-modifying therapies to patients treat patients with CNS, liver/metabolic and cardiovascular diseases.  We are advancing a focused pipeline of innovative gene therapies and have entered late-stage clinical development in our lead indication, hemophilia B, and have established preclinical proof-of-concept in Huntington’s disease.  

Yposkesi

YPOSKESI, based in Corbeil-Essonnes, near Paris (France), is one of the largest European Contract Development and Manufacturing Organizations dedicated to the development and production of gene and cell therapy treatments. The broad expertise of YPOSKESI covers the production of Lentivirus & AAV viral vectors based on transfection processes, for pre-clinical development and clinical trials in compliance with the standards of Good Manufacturing Practice regulations. YPOSKESI benefits from the 30 years viral vector expertise of its long-standing partner, GENETHON, a major player in gene therapies for rare disease.
 
In addition, YPOSKESI has an experienced and efficient team of nearly 190 experts in Bioproduction, Quality Assurance, Quality Control, Project Management and Process Development, operating in a 5,000m² (approx. 53,819 sq ft) modern GMP facility. YPOSKESI is also significantly investing in the development of innovative technologies for large-scale cost-effective manufacturing of these highly complex Advanced Therapeutics Medicinal Products. YPOSKESI plans to extend its production capacity by 2022, with an additional building including two suites dedicated to commercial manufacturing activities with a total of 10,000 m² (approx. 107639 sq ft) space.
 
By forging a solid industrial partnership with the South-Korean SK group, its majority equity shareholder, YPOSKESI reinforced its industrial strategy based on the technological expertise of SK pharmteco, the US SK’s affiliate, complementing that of YPOSKESI, and its solid experience in international manufacturing as a contract manufacturing organisation (CMO).
 

Adverum Biotechnologies

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. ADVM-022, utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 is administered as a one-time intravitreal injection, designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance and improve vision outcomes for wet AMD and diabetic retinopathy patients. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.

ArcticZymes Technologies

ArcticZymes Technologies is a Norwegian biotechnology company which has specialized in unique cold adapted marine enzymes for gene technology applications. These enzymes may simplify workflows due to their unique properties such as salt-tolerance, heat-lability and high activity at low temperatures. All our enzymes are produced recombinantly at very high purity.

ArcticZymes offer unique enzymes for various market segments like manufacturers of molecular diagnostic kit, pharmaceutical bioprocessing, academic research, clinical laboratories and manufacturers of reagents for the Life Science industry.

CellGenix

CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy and regenerative medicine space. We develop, manufacture and market human cytokines and growth factors in preclinical and GMP quality along with GMP serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world.
 
With 25 years of experience we are experts in the GMP manufacturing of raw materials for the cell and gene therapy space. As a former ATMP developer and manufacturer we gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background we understand the high requirements our customers face during product development and the regulatory approval process. By offering expert technical and regulatory support we can help simplify raw material qualification and validation efforts.

Cergentis

Cergentis is a privately held genomics company and has developed and patented the Targeted Locus Amplification (TLA) technology. TLA is a widely published Next Generation Sequencing (NGS) technology that offers unique advantages in the implementation of advanced genetic engineering.
We develop and sell services and in-house solutions for targeted and complete sequencing of (trans)genes and gene editing events and provides services for the support in R&D in these fields. Founded in 2012, Cergentis has established itself as a trusted partner and leader in robust and rapid genetic characterization of genetically engineered cell lines, cell and gene therapy products and transgenic (animal) models for the global biopharmaceutical industry as well as leading research institutes worldwide. It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.
 

e-Zyvec

e-Zyvec is a startup offering services in molecular biology to research laboratories, CROs and Biotech industries that are using genetic engineering approaches.
Our offer is to produce tailor-made ready-to-use gene expression vectors (plasmids) and the expertise to design such molecules so they will really fit our customers’ needs. We are exclusively exploiting a patented DNA assembly method that enable us to modularly assemble vectors from up to 12 DNA fragments in an ordered and seamless way in a single-tube single-step reaction. Our process has been optimized and streamlined so we can carry out multiple assemblies simultaneously.
Building vectors with us is unrestrictive, easy, fast and accurate.
 

GenoSafe

GenoSafe provides analytical testing services for the evaluation of quality, safety and efficacy of Gene and Cell therapy candidates including:
· GLP biodistribution, shedding and immunogenicity studies;
· QC testing, such as viral titration, safety and potency/efficacy testing;
· GCP bioanalysis of patient samples, including immunogenicity, shedding and gene expression studies.
GenoSafe brings more than 15 years of experience in the development, qualification and validation of key analytical methods for product and sample testing.
 

KCT

Lonza AG

At Lonza, we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges.

Together, let’s bring your next medicine to life.

MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.For more information, please visit www.meiraGTx.com.

Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that advance biomedical research and
cellular therapy. Since 1989, we have developed innovative and reliable technologies for scientists
and clinicians around the world. Our integrated portfolio of tools covers techniques of sample
preparation, cell separation, flow cytometry, cell culture, molecular analysis, and preclinical imaging.
The MACS® brand has set standards worldwide and is trusted across basic, translational, and clinical
research settings. Our expertise covers research areas like immunology, stem cell biology,
neuroscience, and cancer, and clinical research areas that include hematology, graft engineering, as
well as apheresis. We are committed to supporting scientists and the scientific community – from
comprehensive technical support to training at our MACS Academy. Today, we are more than 2,000
employees in 22 countries – all dedicated to providing solutions that empower scientific discovery
and advance cellular therapy.
 

Myriade

Myriade is a French company created in 2017 that develops an innovative nanoscale imaging technology: the VIDEODROP. Based on the principles of interferometry, the Videodrop makes it possible to visualize living nanoparticles in the range of 30 nm and 10 microns without labeling, in real time and in a single drop. The Videodrop processing algorithms compute the concentration and size distribution of the nanoparticles and enable to analyze complex mixtures of phages (T4, lambda) for applications in phagotherapy, continuously monitor viral vector solutions (Lentiviruses, adenoviruses) for gene and cell therapy, and distinguish the different types of EVs to vectorize, diagnose or treat.
 
 

OriGen Biomedical

OriGen Biomedical manufactures the industry-preferred products for small volume cell culture and final product cryopreservation. Our products include PermaLife Cell Culture Bag, CryoStore™ Freezing Bag, CryoPur DMSO Solutions and compatible Accessory Sets. Our products are FDA cleared, CE marked, and cGMP manufactured. Connect with us at OriGen.com.
 

PassageBio

At Passage Bio, we are on a mission to provide life-transforming genetic medicines for patients with CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing.
 
As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

Polyplus-transfection

Polyplus-transfection applies its 20 years expertise to the development of novel transfection solutions. Polyplus-transfection is the leading supplier of a key critical component for viral vectors manufacturing for Gene & Cell Therapy. We are proud to provide qualified and GMP-grade transfection reagents suitable from R&D to clinical trial and commercial scale, accompanied by a strong scientific and regulatory support. In addition, we provide a range of effective transfection reagents to deliver most nucleic acids, including DNA and siRNA in vitro and in vivo.
 

Progen

PROGEN, founded in 1983 and located in Heidelberg, Germany is an established manufacturer and supplier of AAV Titration ELISA tests and antibodies for gene therapy research and development.  In the past 20 years, the DIN EN ISO 13485 certified company has established a unique portfolio of AAV tools for basic and clinical research as well as for pharmaceutical applications. Among them are specific antibodies to study AAV assembly, capsid formation or the course of an infection as well as a line of reliable AAV quantification ELISAs for different serotypes utilizing PROGEN’s portfolio of capsid-specific AAV antibodies. PROGEN offers its broad expertise in antibody & ELISA technologies, protein interaction and purification and welcomes collaborations with academic and industrial institutions to advance basic AAV research. In addition, the company aims to establish partnerships with academic, pharmaceutical or medical institutions for the development of AAV-based tools and therapies, e.g. for standardization and validation steps in clinical trials.
 

VGXI Inc

VGXI, Inc. is a leading contract manufacturer of DNA-based pharmaceuticals with 20 years of experience providing high quality cGMP products to clinical trials worldwide. Uses include DNA vaccines, immunotherapies, and cell and gene therapy applications. The company's continuous, low-shear AIRMIX® lysis technology and optimized purification process provide highly supercoiled plasmid with exceptional purity across all manufacturing scales. Production services include high quality plasmid for preclinical research, Highly Documented (HD) plasmid as a critical raw material for GMP viral vector production or pharm/tox studies, and cGMP plasmid DNA for clinical through commercial supply. Pre-Clinical through GMP RNA manufacturing services are also available.
 

VIVET Therapeutics

Vivet Therapeutics is a biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.
 
Vivet’s lead program, VTX-801, is a novel investigational gene therapy for Wilson disease which has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) and the European Commission (EC). This rare genetic disorder is caused by mutations in the gene encoding the ATP7B protein, which reduces the ability of the liver and other tissues to regulate copper levels causing severe hepatic damage, neurologic symptoms and potentially death.
 
Vivet is building a diversified gene therapy pipeline based on novel adeno-associated virus (AAV) with 5 preclinical programs and new technologies addressing key challenges of AAV-based gene therapy related to the sustainability of expression in young patients and immunomodulation for potential retreatment. Vivet develops these technologies through its partnership with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada (CIMA), University of Navarra based in Pamplona, Spain.
 

Astellas Gene Therapies

Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.
 

bluebird bio

Bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company’s novel approach uses stem cells harvested from the patient’s bone marrow into which a healthy version of the disease causing gene is inserted.

Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company.  Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality.  Forge has a 175,000 ft2 facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters.  The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.  By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.
 

Freeline

Greiner Bio-One International GmbH

Greiner Bio-One is a leading partner for the diagnostic and pharmaceutical industry as well as biotechnology with laboratory products made of plastic.
The BioScience division of Greiner Bio-One ranks among the leading providers of specialised products for the cultivation and analysis of cell and tissue cultures. Drawing on decades of experience with cryogenic sample storage, Greiner Bio-One also offers solutions for automated storage systems in biobanks. In addition, we continue to utilise our expertise in the development and production of microplates for high-throughput screening, thereby allowing extremely fast and efficient drug screening for both industrial and research applications. The entire development, manufacturing and sales operations are controlled from the German headquarter of the BioScience division in Frickenhausen.
For detailed information to our products and solutions please refer to our homepage or get in touch with our product specialist:
Dr. Mareike Langbein
Product Manager
M: +49 152 567 71 392
 

Lysogene

Lysogene is a global biotechnology company, a leader in the basic research and clinical development of gene therapy for neurodegenerative disorders. Its mission is to radically improve the health of patients suffering from incurable life threatening conditions by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

Lysogene’s most advanced product candidate is rAAV vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase (hSGSH) for the treatment of MPS IIIA.The recently completed Phase I/II study in four MPS IIIA children demonstrated that the gene therapy and neurosurgical procedure is safe, well tolerated and exploratory efficacy profiles are encouraging (Tardieu 2014).  A phase III clinical study is under preparation.

Following a successful Series A financing round, Lysogene is expanding its pipeline to GM1-gangliosidosis and other genetic diseases affecting the central nervous system.

Merck

Plasmid Factory

PlasmidFactory GmbH & Co. KG is a globally active biopharmaceutical company, founded in Bielefeld, Germany, in 2000. The leading contract manufacturing organization (CMO) for plasmid and minicircle DNA has a strong customer base in the fields of cancer research, gene and cell therapy, CAR-T cell development, and vaccination.
PlasmidFactory produces plasmids and minicircles according to client's requirements in modern laboratories with high quality standards.
The company's R&D activities are focused on its core competencies: Production, analysis and storage of plasmid and minicircle DNA. Furthermore, PlasmidFactory co-operates with national and international partners on individual projects, e.g. in the fields of CAR-T cell, AAV production and mRNA production.

SwanBio Therapeutics

SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions. Our goal is to prevent the progression of debilitating disease and enable the progression of the person. Everything we do echoes the desire to bring hope, improve quality of life, and change the treatment landscape. We are pioneering a deep and varied pipeline of AAV gene therapies for genetically defined neurological diseases with a focus on the spinal cord, starting with our lead indication, adrenomyloneuropathy. Using AAV vectors to deliver genetic corrections leverages the potential of gene therapy, treating the root causes of diseases to provide patients with durable, disease-altering options.
 

Xell AG

Xell is an innovative partner for the biotech and pharmaceutical industry, providing efficient solutions in cell culture technology. Based on its proprietary technology, Xell has developed a range of customized as well as commercial culture media and feeds for the most commonly used mammalian cell types (CHO, HEK, BHK, MDCK, Hybridoma etc). Our chemically defined products are animal-component free and compliant for GMP manufacturing. Apart from the media platform we offer fast and reliable analytical services - among others, proprietary methods for amino acid, vitamin, (trace) element, organic acid or polyamine analyses. Additionally, cell culture and process services are provided to better understand cellular behavior and optimize cultivation processes. At our production site, we offer large scale production of liquid and powder media as well as related solutions approved by ISO 9001 QMS.